4Q EARNINGS ROUNDUP: Alexion, Vertex and Baxter
This article was originally published in Scrip
Sometimes a leadership change-up can drive a company's stock lower as investors worry about how the new chief executive will run the business, but Alexion Pharmaceuticals closed 5.8% higher at $188.05 per share on 29 January after the company said founder and CEO Leonard Bell will retire, but announced a 44% increase in annual net product sales and a 69% rise in non-GAAP earnings per share (EPS).
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.